Mesenchymal stem cells in cardiology

Ian A. White, Cristina Sanina, Wayne E Balkan, Joshua Hare

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Citations (Scopus)

Abstract

Cardiovascular disease (CVD) accounts for more deaths globally than any other single disease. There are on average 1.5 million episodes of myocardial infarction (heart attack) each year in the United States alone with roughly one-third resulting in death. There is therefore a major need for developing new and effective strategies to promote cardiac repair. Intramyocardial transplantation of mesenchymal stem cells (MSCs) has emerged as a leading contender in the pursuit of clinical intervention and therapy. MSCs are potent mediators of cardiac repair and are therefore an attractive tool in the development of preclinical and clinical trials. MSCs are capable of secreting a large array of soluble factors, which have had demonstrated effects on pathogenic cardiac remolding, fibrosis, immune activation, and cardiac stem cell proliferation within the damaged heart. MSCs are also capable of differentiation into cardiomyocytes, endothelial cells, and vascular smooth muscle cells, although the relative contribution of trilineage differentiation and paracrine effectors on cardiac repair remains the subject of active investigation.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages55-87
Number of pages33
Volume1416
DOIs
StatePublished - 2016

Publication series

NameMethods in Molecular Biology
Volume1416
ISSN (Print)10643745

Fingerprint

Cardiology
Mesenchymal Stromal Cells
Myocardial Infarction
Mesenchymal Stem Cell Transplantation
Vascular Smooth Muscle
Cardiac Myocytes
Smooth Muscle Myocytes
Fibrosis
Cardiovascular Diseases
Stem Cells
Endothelial Cells
Cell Proliferation
Clinical Trials
Therapeutics

Keywords

  • Cardiology
  • Cardiovascular Disease
  • Clinical trial
  • Mesenchymal stem cell
  • Myocardial infarction

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

White, I. A., Sanina, C., Balkan, W. E., & Hare, J. (2016). Mesenchymal stem cells in cardiology. In Methods in Molecular Biology (Vol. 1416, pp. 55-87). (Methods in Molecular Biology; Vol. 1416). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3584-0_4

Mesenchymal stem cells in cardiology. / White, Ian A.; Sanina, Cristina; Balkan, Wayne E; Hare, Joshua.

Methods in Molecular Biology. Vol. 1416 Humana Press Inc., 2016. p. 55-87 (Methods in Molecular Biology; Vol. 1416).

Research output: Chapter in Book/Report/Conference proceedingChapter

White, IA, Sanina, C, Balkan, WE & Hare, J 2016, Mesenchymal stem cells in cardiology. in Methods in Molecular Biology. vol. 1416, Methods in Molecular Biology, vol. 1416, Humana Press Inc., pp. 55-87. https://doi.org/10.1007/978-1-4939-3584-0_4
White IA, Sanina C, Balkan WE, Hare J. Mesenchymal stem cells in cardiology. In Methods in Molecular Biology. Vol. 1416. Humana Press Inc. 2016. p. 55-87. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3584-0_4
White, Ian A. ; Sanina, Cristina ; Balkan, Wayne E ; Hare, Joshua. / Mesenchymal stem cells in cardiology. Methods in Molecular Biology. Vol. 1416 Humana Press Inc., 2016. pp. 55-87 (Methods in Molecular Biology).
@inbook{c1e5b7dff2fa4df4a5c2e7fce5b54721,
title = "Mesenchymal stem cells in cardiology",
abstract = "Cardiovascular disease (CVD) accounts for more deaths globally than any other single disease. There are on average 1.5 million episodes of myocardial infarction (heart attack) each year in the United States alone with roughly one-third resulting in death. There is therefore a major need for developing new and effective strategies to promote cardiac repair. Intramyocardial transplantation of mesenchymal stem cells (MSCs) has emerged as a leading contender in the pursuit of clinical intervention and therapy. MSCs are potent mediators of cardiac repair and are therefore an attractive tool in the development of preclinical and clinical trials. MSCs are capable of secreting a large array of soluble factors, which have had demonstrated effects on pathogenic cardiac remolding, fibrosis, immune activation, and cardiac stem cell proliferation within the damaged heart. MSCs are also capable of differentiation into cardiomyocytes, endothelial cells, and vascular smooth muscle cells, although the relative contribution of trilineage differentiation and paracrine effectors on cardiac repair remains the subject of active investigation.",
keywords = "Cardiology, Cardiovascular Disease, Clinical trial, Mesenchymal stem cell, Myocardial infarction",
author = "White, {Ian A.} and Cristina Sanina and Balkan, {Wayne E} and Joshua Hare",
year = "2016",
doi = "10.1007/978-1-4939-3584-0_4",
language = "English (US)",
volume = "1416",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "55--87",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Mesenchymal stem cells in cardiology

AU - White, Ian A.

AU - Sanina, Cristina

AU - Balkan, Wayne E

AU - Hare, Joshua

PY - 2016

Y1 - 2016

N2 - Cardiovascular disease (CVD) accounts for more deaths globally than any other single disease. There are on average 1.5 million episodes of myocardial infarction (heart attack) each year in the United States alone with roughly one-third resulting in death. There is therefore a major need for developing new and effective strategies to promote cardiac repair. Intramyocardial transplantation of mesenchymal stem cells (MSCs) has emerged as a leading contender in the pursuit of clinical intervention and therapy. MSCs are potent mediators of cardiac repair and are therefore an attractive tool in the development of preclinical and clinical trials. MSCs are capable of secreting a large array of soluble factors, which have had demonstrated effects on pathogenic cardiac remolding, fibrosis, immune activation, and cardiac stem cell proliferation within the damaged heart. MSCs are also capable of differentiation into cardiomyocytes, endothelial cells, and vascular smooth muscle cells, although the relative contribution of trilineage differentiation and paracrine effectors on cardiac repair remains the subject of active investigation.

AB - Cardiovascular disease (CVD) accounts for more deaths globally than any other single disease. There are on average 1.5 million episodes of myocardial infarction (heart attack) each year in the United States alone with roughly one-third resulting in death. There is therefore a major need for developing new and effective strategies to promote cardiac repair. Intramyocardial transplantation of mesenchymal stem cells (MSCs) has emerged as a leading contender in the pursuit of clinical intervention and therapy. MSCs are potent mediators of cardiac repair and are therefore an attractive tool in the development of preclinical and clinical trials. MSCs are capable of secreting a large array of soluble factors, which have had demonstrated effects on pathogenic cardiac remolding, fibrosis, immune activation, and cardiac stem cell proliferation within the damaged heart. MSCs are also capable of differentiation into cardiomyocytes, endothelial cells, and vascular smooth muscle cells, although the relative contribution of trilineage differentiation and paracrine effectors on cardiac repair remains the subject of active investigation.

KW - Cardiology

KW - Cardiovascular Disease

KW - Clinical trial

KW - Mesenchymal stem cell

KW - Myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84990230741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990230741&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3584-0_4

DO - 10.1007/978-1-4939-3584-0_4

M3 - Chapter

C2 - 27236666

AN - SCOPUS:84990230741

VL - 1416

T3 - Methods in Molecular Biology

SP - 55

EP - 87

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -